ERBB2 and triple-negative breast carcinoma: In particular, triple-negative breast cancer (TNBC) has low or absent estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2), so it lacks effective targeted therapies and is associated with a poor prognosis [7,8,9,10].